Exagen Inc. (XGN) Tops Q3 EPS by 29c

Exagen Inc. (NASDAQ: XGN) reported Q3 EPS of ($0.47), $0.29 better than the analyst estimate of ($0.76). Revenue for the quarter came in at $14.7 million versus the consensus estimate of $9.13 million.

GUIDANCE:

Exagen Inc. sees FY2022 revenue of $40-43 million, versus the consensus of $38 million.

For earnings history and earnings-related data on Exagen Inc. (XGN) click here.

You May Also Be Interested In

• Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
• Equinor ASA (ADR) (EQNR) PT Lowered to $37 at TD Cowen
• InTest joins Russell 2000 and Russell 3000 indexes